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Abstract
In most neuropathological conditions, robust activation of brain innate immunity
occurs. Central nervous system (CNS) innate immune response is characterised
by the engagement of the two arms of innate immunity (Complement System and
Toll-like receptors, TLRs) and by the activation of neurons, microglia and astro-
cytes, resulting in rapid production of inflammatory cytokines and chemokines via
activation of signal transduction pathways, i.e., NF-κB.
In this thesis we studied the possible role of MyD88 adaptor-like (Mal)/TIRAP
in functional recovery and neuronal survival following sterile peripheral facial nerve
axotomy and nerve crush in wild type (WT) and Mal knock out (KO)-mice. Periph-
eral facial nerve injury leads to a total paralysis of whiskers and functional recovery
of whisker movement following injury occurs over time. Recovery of whisker vi-
bration and whisker movement was monitored for 31 days post axotomy. We have
demonstrated that during the first 14 days post lesion the functional regeneration
of the facial nerve was similar in axotomised WT- and MalKO-mice, except for
a slight onset delay in MalKO-mice. In WT-mice ongoing functional recovery of
whisker movement and vibration was observed, while MalKO-mice show growing
impairment after day 14.
Cell counts after 31 days show a significantly higher motoneuron survival in WT-
mice (60,1%) compared to MalKO-mice (50,4%). Additionally we determined rel-
ative protein levels of GFAP, SHP-1, IRAK-1 and CD11-b. Relative GFAP levels
are distinctly elevated in MalKO mice compared to WT mice while relative Shp-1
levels are reduced as well as relative IRAK-1 levels, suggesting an increased inflam-
matory response in MalKO-mice following peripheral injury. These results suggest
that innate immune mechanisms associated to Mal/TIRAP signalling play a role in
regulation of motoneuron survival and therefore also functional recovery following
sterile facial peripheral nerve injury.
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Zusammenfassung
Die meisten neuropathologischen Krankheiten lo¨sen eine ausgepra¨gte Aktivierung
des angeborenen Immunsystems im Gehirn aus. Diese ist einerseits durch Beteili-
gung der zwei Hauptbereiche des angeborenen Immunsystems charakterisiert (Kom-
plement System und Toll-like Rezeptoren) und andereseits durch die Aktivierung
von Neuronen, Mikroglia und Astrozyten, welche u¨ber Signalwege, wie zum Beispiel
den NF-κB-Weg, in rapider Produktion von entzu¨ndungsauslo¨senden Cytokinen und
Chemokinen resultiert.
In diesem Projekt wurde untersucht welche Bedeutung MyD88 adapter-like(Mal)/
TIRAP im Kontex von funktioneller Regeneration und dem U¨berleben der betrof-
fenen Neuronon nach steriler, peripherer Gesichtsnervaxotomie und Gesichtsnerv-
quetschung in WT- und KO-Ma¨usen zukommt. Diese Verletzungen fu¨hren zu totaler
Paralyse der Schnurrhaare, mit funktionaler Regeneration die wa¨hrend der darauf-
folgenen Wochen stattfindet. Die Regeneration von Vibration und Bewegung der
Schnurrhaare wurde fu¨r einen Zeitraum von 31 Tagen u¨berwacht. Wie wir zeigen
konnten, verlief die Heilung der Schnurrhaarbewegung und -vibration in WT- und
MalKO-Ma¨usen wa¨hrend der ersten Periode von 14 Tagen parallel, zu Anfang mit
minimaler Verzo¨gerung in MalKO-Ma¨usen. Daran anschließend setzte sich in WT-
Ma¨usen die Regeneration relativ stetig fort, wa¨hrend in MalKO-Ma¨usen wachsende
Verschlechterung beider Parameter zu beobachten war. Dazu passend wurde 31 Tage
nach Axotomie eine signifikante Differenz in der Zahl der u¨berlebenden Neuronen
zwischen WT-Ma¨usen (60,1%) und MalKO-Ma¨usen (50,4%) beobachtet. Zusa¨tzlich
wurden die relativen Proteinlevel von GFAP, SHP-1, IRAK-1 und CD11-b fest-
gestellt. Die relativen Proteinlevel von GFAP war in MalKO-Ma¨usen im Vergleich
zum WT deutlich erho¨ht wa¨hrend sie fu¨r SHP-1 ebenso wie fu¨r IRAK-1 reduziert
waren, was auf eine erho¨hte Entzu¨ndungsantwort in MalKO-Ma¨usen hindeutet.
Diese Ergebnisse geben Anhaltspunkte dafu¨r, dass angeborene Immunmechanismen
in Verbindung mit Mal/ TIRAP Signalwegen eine nicht zu unterscha¨tzende Rolle in
der Regulation von Motorneuronen-U¨berleben und damit funktioneller Regeneration
nach einer sterilen Gesichtsnervenverletzung in der Peripherie spielen.
1 Introduction
Innate immunity is the first line of sensors for and defence against environmental
pathogens and also an important regulator of the adaptive immune system. Toll like
receptors (TLRs, pattern recognition receptors) and complement system are the two
pillars of the innate immune response against pathogens.
1.1 TLR
TLRs are trans-membrane receptors that contain leucine rich repeats (LRR) in the
ectodomain, a trans-membrane domain and a Toll-IL-1R (TIR) domain on the in-
tracellular part, representing an essential part for signal transduction [1] in innate
immune responses. Activation of TLRs hence induces a tightly controlled signalling
cascade which - overstimulated - can lead to severe inflammatory auto immune
diseases [2]. TLRs are highly conserved and get activated mainly by specific muta-
tion resistant molecular patterns found in pathogens so called pathogen-associated
molecular patterns (PAMPs) [3, 4].
TLRs can be activated by various stimuli, nearly all of them pathogen associated
molecular patterns (PAMPs), like LPS or RNA and others molecules found on the
surface or in debris of pathogens [3]. This can lead to the induction of several
different transcription factors like interferon regulatory factors (IRFs), activating
protein-1 (AP-1) and nuclear factor-κB (NFκB), which in turn modulate specific
immune responses.
10
1.1.1 Types and occurrence of TLRs
To date there are 13 different TLRs that have been identified. TLR-1 and TLR-2
are known to form heterodimers and detect bacterial triacylated lipopeptides, how-
ever, if building a heterodimer with TLR-6, TLR-2 recognises bacterial diacylated
lipopeptides. One of the strongest known triggers for the innate immune system –
LPS – is identified by TLR-4, building a homodimer as well as TLR-9 which de-
tects unmethylated CpG containing DNA-motifs of bacteria and viruses. TLR-3 –
binding viral double-stranded RNA (dsRNA) - and TLR-5, which senses flagellin
from bacteria, are also thought to build homodimers. Single stranded (ss) viral
RNA is bound by TLR-8 that has been shown to dimerise with TLR-7 and 9 and
to antagonise signalling by TLR-7 or TLR-9 [5]. TLR-10 has shown to be able to
homodimerise but also to build heterodimers with TLR-1 and TLR-2 [6]. TLR-11
recognises profilin of protozoan parasites [7] but have also been shown to react on
uropathogenic bacteria [8, 9]. Ligands for TLR-10, TLR-12 and TLR-13 still remain
to be identified.
TLRs are known to be expressed in a wide variety of cells including cells of the
immune systems like microglial cells in the brain as well as astrocytes, epithelial
cells and also endothelial cells [4]. Thus, it has been shown, that in different cell
types different responses are triggered via different signalling pathways by the same
type of TLR.
1.1.2 Signalling pathways and results of TLR activation /
adaptors / mechanisms
TLRs are thought to occur in low affinity complexes where the dimers are loosely
pre-assembled but not yet tightly bound. Conformational changes necessary to
create a TIR-TIR-interface on the cytosolic surface takes place after ligand binding.
Evidence suggests that TLRs get in closer proximity after ligand binding and create
a platform for the signalling complex to be built, although the crystal structure as
evidence for this platform remains to be elucidated [2].
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TLR Adaptors
The next level in signal transduction is represented by the TLRs associated adaptor
proteins. Five different adaptors have been identified so far: myeloid differentiation
factor – 88 (MyD88), MyD88 adaptor-like protein (MAL) also known as Toll-IL-1
Receptor adaptor protein (TIRAP), TIR domain containing adaptor protein induc-
ing IFNβ (TRIF), TRIF related adaptor molecule (TRAM) and sterile alpha and
armadillo-motif-containing protein (SARM).
MAL / TIRAP MAL was found to be one of the essential factors for an early im-
mune response in several different infections [10-13]. One of its major characteristics
is its electro-negativity. Most of the TLRs are electronegative and bind well with
MyD88, being electro-positive. TLR2 and TLR4 though, need the electronegative
MAL as a bridging adaptor as themselves are largely electro positive and there-
fore not able to bind MyD88 directly [14, 15]. Its PIP-2 (phosphatidylinositol-4,5-
bisphosphate) binding site on the N-terminus recruits MAL to the plasma membrane
in the direct vicinity to TLR2 and TLR4 [16]. Absence of MAL or MyD88 leads to
massively impaired immune responses upon stimulation of TLR 2 and 4 in vivo and
in vitro. TNF-production is abolished and only a delayed induction of NFκB takes
place [2]. Tyrosin phosphorylation of MAL also renders it subject to degradation
mediated by SOCS1 (Suppressor of cytokine signalling 1)[17]. This represents a
highly important regulation against hyperactivation through LPS, as demonstrated
in SOCS1 deficient cells [17, 18], MalKO-cells show no activation of NFκB or p38
via the TLR2 pathway. They also exhibit only a delayed NFκB activation via the
MyD88 independent signal transduction of TLR4 via TRIF [19, 20].
Caspase-1 cleaves a C-terminal part of MAL, a modification essential for its func-
tion. This was shown by the addition of caspase-1 inhibitor ZVAD-Cmk inhibiting
NFκB activation by LPS and therefore abolishing a major pro-inflammatory path-
way. Phosphorylation of p38 in response to Pam3Cys linking caspase-1 activity was
also shown to be abolished [22]. Phosphorylation of MAL via the tyrosines (tyr) 86,
106, 159 [23, 24] or according to [25] phosphorylation of tyr 86, 106 and 187 leads to
its activation. Mutations in those tyrosines cause decreased ability to induce p-38
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Figure 1: Activation of NF-κB via TLR2 and TLR4. Mal (TIRAP) acts
as a bridging adaptor for MyD88. Subsequently activated NF-
κB becomes active and enters the nucleus and induces several
target genes. (Figure adapted from [21])
phosphorylation, IκBα degradation and NFκB activation upon activation by LPS.
It has been shown that MAL with tyr86 and tyr187 substituted by phenylalanine,
acts as a dominant negative inhibitor of LPS signalling [23, 24]. MAL also seems
to play an important role in LPS-tolerance, as studies have shown decreased MAL
Protein levels in the restimulation of LPS-tolerised cells.
The importance of MAL has also been shown in the MAL S180L polymorphism.
This polymorphism has shown to be protective against Malaria, Tubercolosis (TB),
Bacteremia and IPD (invasive pneumococcal disease) in heterozygous form. It ap-
pears to prevent the harmful over production of inflammatory cytokines by atten-
13
uating NFκB activation but inducing signalling sufficiently strong for host defence
[26]. When reintroduced in MalKO cells, the MAL S180L polymorphism shows no
activation of NFκB and, supporting those results was shown to prevent binding
between MAL and activated TLR2. Another key player involved in signalling via
TLR2 and TLR4 / MAL has been discovered to be Brutons tyrosine kinase (Btk).
LPS induces tyrosine phosphorylation of Btk (a member of the Tec family) leading
to activation of its kinase activity. Btk then phosphorylates and activates MAL.
Furthermore, Btk has been shown to interact with the TIR domains of the TLRs
4,6,8 and 9 and associate with IRAK-1 (MyD88, MAL and IL-1 receptor associated
kinase 1) [27, 28]. Thus X-linked agammaglobulinaemia monocytes presenting a
mutation of Btk are unresponsive to LPS. It is also likely to be a main upstream
target in regulation during LPS-tolerance.
IRAK-1 as well as IRAK-4 also belong to the group of proteins, modifying MAL.
Experiments have shown degradation of MAL in co-expression with either of them.
Furthermore the knock down of IRAK-1 and IRAK-4 or in the presence of IRAK-
1 and IRAK-4 inhibitors LPS dependent MAL ubiquitination and degradation is
inhibited. This seems to be responsible for a negative feedback loop in TLR2 and
TLR4 signalling as well [29].
Another characteristics of MAL is its tumor necrosis factor receptor-associated
factor 6 (Traf6) binding site. Reconstituting a TRAF6- binding site mutated form
of MAL in MAL deficient murine macrophages shows the importance of this bind-
ing site as it doesn’t restore a pro-inflammatory immune response to TLR2 and
TLR4 activation. Although MAL and TRAF6 interact directly, membrane locali-
sation is not necessary [30]. Interaction between MAL and TRAF6 leads to serine-
phosphorylation of the p65 subunit of NFκB, controlling transcriptional activation
but not nuclear translocation. MAL also facilitates direct recruitment of TRAF6
to the plasma-membrane in vicinity of TLR2 and TLR4 to induce a subsequent
pro-inflammatory response via NFκB activation [30].
From all above described it seems that MAL plays a fundamental role in the
signalling pathways following TLR2 and TLR4 activation. Signalling through TLR2
and TLR4 have been shown to be important not only during bacterial infections but
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also in neuro-inflammatory processes in the CNS and this is what we intended to
demonstrate in this work.
1.2 Glial cells
For a long time glial cells were considered to provide only maintenance functions
to the key players of nervous tissue, i.e. neurons. The so called nerve glue was
thought to be responsible for transporting nutrients to and waste from the neurons
and provide stability for the structure of the neuronal networks. This view has
changed fundamentally over the last decades and glial cells have been demonstrated
to play a fundamental role in synaptic activity and neuronal plasticity by supporting
neuronal and synaptic function in the central nervous system [31, 32]. They also
play a role in the preservation of the host tissue integrity following injury [33] and in
the CNS immune response and following peripheral and central nerve degeneration
and regeneration [34] as well as learning and memory and neuronal plasticity.
1.2.1 Types
Glial cells are divided in three different main categories, astrocytes, oligodendrocytes
and microglia. Each carrying out distinct functions in the complex network of the
nervous system.
Oligodendrocytes
Oligodendrocytes form myelin, a lipid rich membrane, tightly and in several lay-
ers wrapped around axons to facilitate saltatory action potential propagation by
electrical insulation. Action potentials jump from one Node of Ranvier (the small
exposed space between two wraps, where ion-channels are found in high density)
to the next, therefore ensuring faster signal transmission. One oligodendrocyte can
wrap up to 50 axonal segments on surrounding neurons [35]. Various conditions, es-
pecially auto-immune diseases like multiple sclerosis have clearly shown how crucial
the function of oligodendrocytes in signal transmission is.
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Astrocytes
Astrocytes were traditionally thought to be only support for the neurons and known
to regulate ion concentrations in the synaptic environment. They were also shown to
provide for metabolic needs of neurons during synaptic transmission by ensheathing
the neuronal synapses and regulating concentrations of ions and neurotransmitters in
the synaptic cleft [36 or 37, 38]. However the knowledge about the role of astrocytes
has massively changed during the last two decades. Cells classified as astrocytes are
in fact a group of celltypes with specific phenotypical and biochemical characteris-
tics. In principle all have a stellate morphology while the processes grow radially in
all directions, spreading over a domain of around 200 µm diameter [39]. They rep-
resent more than 50% of cells in the CNS and are organised in glial networks. Long
distance communication takes place via gap junctions established between adjacent
processes of two astrocytes [40]. Probably the broadest distinction to make is the
difference between protoplasmic astrocytes in the grey matter which are ensheathing
synapses and fibrous astrocytes in the white matter, insulating the nodes of Ranvier.
However, there exist also highly specialised types of astrocytes such as Bergmann
glia in the cerebellum and Muller glia of the retina [41]. Muller glia show charac-
teristics of immature astrocytes as they express vimentin [42]. Additionally the cell
membranes of astrocytes exhibit a great variety of specialisation, dependent on the
area or contact site they are in. For example in close proximity to the synaptic cleft
various kinds of ligand- or voltage-gated ion channels and transporters [43] can be
found in the astrocytic membrane.
Astrocytes interact with neurons, microglia and blood vessels and communicate
mostly via neurotransmitters but also via gap junctions [39]. Generally resting
astrocytes are star shaped cells with long processes growing out in all directions
[40]. Thus astrocytes have been shown in vivo and in vitro to respond via calcium
signalling to a great variety of physiological and pathological stimuli [39].
Activation of Astrocytes Activated astrocytes play a major role following nervous
tissue injury, CNS trauma and in a number of neuroimmunological and neuroinflam-
matory conditions. Astrocyte activation in response to injury takes place in several
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gradual stages and is highly dependent on timing, characteristics and severity of the
injury. In the early stages of activation, astrocytic morphology and GFAP expres-
sion changes, depending on and regulated by neuronal activity [42]. In later stages
astrocytes show increased levels of GFAP and Chemokines, and increased protein
levels of TLRs. Also gradually, dependent on duration and severity of the stimulus,
a set of different pro and anti-inflammatory cytokines is secreted by these cells [42,
44].
Following neuronal injury activated astrocytes can withdraw their protrusions
from a neuron which brings them one step further towards cell death. At the same
time release of neurotrophic factors by astrocytes can facilitate regeneration and
repair. However, it can also lead to glial scar formation within the CNS, which,
in turn, can impair nervous outgrowth and full reinnervation and regeneration [45].
Thus, it seems likely, that activation of astrocytes and the active involvement of
the astrocytic network can have both, positive and negative outcomes, depending
on circumstances and triggers involved. Also the ability to move molecules between
extracellular and intracellular space renders them an important player in all kinds
of CNS and nerve injury. Astrocytes are likely to determine the tissue response and
partly the amount of tissue damage [46]. Glutamate, although being a neurotrans-
mitter is toxic at elevated concentrations. Transporters present in the astrocytes
membrane uptake glutamate from the extracellular space and help therefore pre-
venting excitotoxic damage. They also buffer K+, and deal with free radicals -
these are some of the neuroprotective astrocytic functions [47]. Neurons and glia
can release pathological amounts of glutamate in case of traumatic injury or is-
chemia [48]. However, the protecting function of astrocytes can be reduced in an so
called Excitatory Crisis and in the worst case will be reversed, resulting in elevated
damage to the neuronal network [49]. Again, activated astrocytes are active in both,
protective and damaging processes.
Microglia
Microglia are cells of the immune system and developmentally derived from bone
marrow precursor cells. Representing about 10-20% of all glial cells, microglia are
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considered to be the macrophages of the brain. At rest they constantly extend and
retract highly motile processes covering a 30 to 50 µm wide area in order to keep the
parenchyma under tight surveillance and scan for any sign of tissue damage. Mi-
croglia are considered to build the first line of defence against injury in the brain and
get activated by any abnormal substances like lipopolysaccharide (LPS), proinflam-
matory cytokines or cell necrosis factors [50]. Moreover neurons can also modulate
the activation status of microglia via neurotransmitters or neuromodulators [51].
Figure 2: Schematic view of the stages of microglial activation. [81]
Activation of microglia Microglial activation - as is the case for astrocytes is
characterised by phenotypical biochemical, structural and functional changes in a
multi-stage process. Once activated, microglia loose their ramified morphology.
The rather small cell body becomes noticeably thicker and the protrusions shorten
and thicken, giving the microglial cell an amoeboid shape in which cells become
motile Fig. ?? . Microglial cells then start to express cell surface proteins typical
for antigen-presenting cells (APCs) like T- and B-lymphocyte markers, immune cell
antigens and major histocompatibility complex (MHC) antigen. At the same time
a massive proliferation takes place, to elevate the rather low numbers of microglial
cells in place to accomplish their neuroimmune functions [51]. Microglia then start
to migrate towards the lesion. Included in the changes occurring during activa-
tion, microglia also gain the ability of phagocytosis, and secrete proinflammatory
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cytokines leading to more activated cells, but also start removing the activating
antigen, engulfing debris that could lead to further inflammation and tissue injury.
This helps to prevent enhancement of inflammation. Once activated they are also
capable of producing N-methyl-D-aspartate (NMDA) receptor agonists [52] as well
as free oxygen radicals [53] and nitric oxide [54] all being potentially neurotoxic.
However, microglia also secrete growth factors like transforming growth factor-β1
(TGF-β1) [55], facilitating tissue regeneration and damage repair.
1.2.2 Glial activation and communication between microglia and
astrocytes
Microglial and astrocytic activation are linked very closely although occurring at
different time-points. In comparison, microglia are activating earlier and are more
sensitive than astrocytes as it has been shown for experimental autoimmune en-
cephalomyelitis (EAE) [56] and Alzheimer’s disease [57]. In a model for neurode-
generation, (the administration of Trimethyltin (TMT) a chemical causing massive
neuronal death already at a low dose) Microglial response was already measured in
non-neurotoxic conditions [51] while astrocytic activation (with GFAP as indicator
for astrocytic activation) was observed to take place at a later time compared to
microglial activation [58]. This shows evidence for microglial cells responding more
sensitive and also earlier than astrocytes.
Astrocytes - once activated - in turn activate distant microglia and alter the
microglial response [51]. Distant activation was originally thought to take place
only by calcium waves propagating along astrocytic networks. Later, adenosine
triphosphate (ATP) was found to be another key player in the signal transmission.
Microglia have been observed to express purinic receptors and getting activated by
ATP [51].
Besides all these damage exacerbation, astrocytes have been found to have an
inhibitory effect in their communication with microglia. They help preventing dam-
age by inhibiting NO, reactive oxygen species (ROS) and TNF-α secretion [51]. In
addition TGF-β has been found to be the responsible factor for deactivating mi-
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croglia and attenuating chemotactic migration towards the injured site [59]. TGF-β
reverses a lot of modifications occurring during microglial activation. It also leads to
down-regulation of surface molecules responsible for antigen presentation and secre-
tion of proinflammatory cytokines and radicals [60, 61]. Additionally the activation
of NF-κB and the following upregulation of IL-1 mRNA levels was shown to be
reduced by pretreatment of microglial cell cultures with TGF-β [51].
1.2.3 TLRs in glial inflammation
TLRs as a family of pattern recognition receptors are well known to play a major role
in CNS innate immune responses to infectious diseases. Recent data also indicate
participation of TLRs in tissue injury, neurodegeneration and autoimmunity. Glial
cells express several types of TLRs, particularly when activated but evidence can also
be found for TLR2 and TLR4 to be expressed constitutive in different brain areas.
TLRs 2 and 4, which are both interacting with MAL during signal activation, are
relevant for this thesis and are both expressed on microglia as well as on astrocytes.
Even microglial apoptosis in an TLR2-dependent manner was shown to occur, likely
to prevent bystander damage [21, 49]. Their functional significance in astrocytes
remains subject to further studies.
1.3 Post-lesional plasticity – Nerve regeneration
1.3.1 The rodent facial nerve axotomy model
The rodent facial nerve axotomy model is one of the most used and best known and
studied models for nervous injury and following degeneration and regeneration of the
nucleus as well as functional recovery in vivo. This particular model provides sev-
eral advantages. First and foremost it provides a paired experimental system with a
direct control in the contralateral facial nerve and facial nucleus. The surgical pro-
cedure is comparably easy and is only of mild severity. The chance of contamination
of the nucleus by blood is very low as no breach of the blood brain barrier happens.
Also the site of the injury is far enough away from the actual nucleus and no CNS
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Figure 3: Schematic view of a classical motoneuron with cell body in the CNS and axonal
endplate in the periphery [with friendly permission of Dr. A. Campos-Torres].
trauma takes place [62, 63]. Representing several different experimental systems in
one, this system also is well studied in terms of different severities of lesions like
nerve avulsion, nerve transsection and nerve crush. Depending on severity of the
lesion and distance of the lesion to the cell nucleus, neuronal cell death is more or
less likely to take place [64]. Major differences have shown between different species.
For example in mice a significant infiltration of the facial nucleus with activated T-
lymphocytes takes place in the later stages (around 14 to 30 days) of neuronal cell
death. Activated microglial cells are thought to act as antigen presenting cells in
this process. They are starting phagocytosis and expressing a high levels of major
histocompatibility complex (MHC) class I and II molecules [65].
Anatomy of the facial nerve model
The facial nerve is the 7th of 12 paired cranial nerves. In all mammals the motor
branch controls the muscles of facial expression and functions. Its sensitive branch
plays a role in taste sensations of the anterior two thirds of the tongue. The facial
nucleus is located in the furthest ventral part of the posterior pons and the anterior
medulla in the brain stem. The facial nerve leaves the skull at the level of the
stylomastoid foramen and divides into two branches. The lower branch and part
of the upper branch innervates the vibrissae follicular muscles. The second part of
the upper branch leads up to the eye and is responsible for the nictitating reflex
[66, 67]. The facial nucleus is divided in several sub-nuclei, reaching into the above
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Figure 4: Anatomy of the facial nerve model. (A) Facial nuclei (hatched areas) located furthest
ventral in the posterior pons. Facial nerve trajectors around the nucleus abducens indi-
cated by the small arrow and leaves the skull at the levels of the stylomastoid foramen.
The facial nerve is cut 2 mm after (big arrow). (B) Schematic drawing of the facial
nerve depicting the branching out into an upper part and a lower part. The place of the
axotomy is indicated by the black arrow [A: adapted from [65], B: adapted from [67].
described different branches of the facial nerve. However, motoneurons themselves
are considered to be very heterogenous in terms of size and shape, although the
arrangement mirrors the innervation in the whiskers, with the neurons innervating
rostral whisker muscles are found laterally while the ones, representing the caudal
whisker muscles are located medially in the facial nucleus [68].
Regeneration in the rodent facial nerve axotomy model
Peripheral nerve axotomy was shown to elicit a strong tissue response of the micro-
environment of the corresponding area in the CNS as well as in the affected nerve cell
bodies. Consistent with those findings, energy turnover and enzymatic activity in
the involved neurons increases. However, axonal reactions appear to be completely
independent from retrograde transport in the injured motor neuron. Microglial cells
and astrocytes become activated and - together with the affected neurons - start
a well organised regeneration programme. This involves increasing expression of
adhesion molecules with simultaneously reducing functions and protein expression
involved in classical neuronal transmission.
Other changes taking place during regeneration are so called “synaptic stripping”
and loss of synaptic boutons. This is followed by sheet like lamellar extensions of
astrocyte processes which cover all the areas of bouton loss. Astrocytes seem to play
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a major role in protecting the regenerating neuron from phagocytosis by microglia
[65]. Microglia also seem to play a protective role by secreting glutamate, helping
to maintain glutamate homoeostasis [65].
In order to allow neurite outgrowth debris derived from the axotomised part of the
axon has to be removed. It takes about 4 weeks post transection for re-innervation of
the target musculature. Several neurotrophic and growth factors like Brain-Derived
Neurotrophic Factor (BDNF) and Nerve Growth Factor (NGF) have been shown
to play an essential role in the regeneration process, although recovery of function
seems to be barely affected by these growth factors and has been found to be limited
or even unchanged [65].
Loss of motor neurons in the peripheral facial nerve axotomy seems to be species
dependent and ranges at up to 50% in mice while in rats depending on strains about
80% of motor neurons survive the procedure.
1.4 Aim of the project: Investigating the role of MAL
in Facial motor neuron survival and functional
facial nerve recovery in response to peripheral
nerve injury
The aim of the project for this thesis was to study the role of MAL/TIRAP sig-
nalling after nervous injury. This included the impact on glial activation following
peripheral facial nerve axotomy. Additionally the influence of MAL/TIRAP on facial
motor neuron survival after the lesion and functional recovery of whisker movement
following peripheral facial nerve axotomy within a window of 31 days was under
investigation to get a more comprehensive picture.
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2 Material and Methods
2.1 Material
2.1.1 Genotyping
• RNA extraction kit: RNeasy FFPE Kit (50) [Quiagen]
• reverse transcription (RT):
– polymerase: M-MLV Reverse Transcriptase, 50000 u, 200 u/µl [Promega]
– M-MLV RT 5x Buffer M531A, 23713920, [Promega]
– RNasin RNase Inhibitor, 10000 u, 40 u/µl [Promega]
– Deoxynucleotide Solution Mix #N0447L, 10 mM each dNTP [Biolabs]
• polymerase chain reaction (PCR):
– Primers:
∗ MAL A: 5’-CATCCTGTGTGGCTGTCTGTGAACCAT-3’
∗ MAL B: 5’-TGGCCAATGTGTGAGCAAGTTCTGTGC-3’
∗ MAL C: 5’-ATCGCCTTCTATCGCCTTCTTGACGAG-3’
– HotMasterMix(2,5x) [Eppendorf]
– Thermo Cycler: Light Cycler [Roche]
• agarose gel:
– agarose: [FISHER]
– 1x TAE: 40 mM Tris acetate, 1 mM EDTA (ethylenediamine tetraacetic
acid, pH 8.0
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– marker: Gene Ruler (TM) Ultra Low Range DNA Ladder, 0,1µg/µl,
[Fermentas]
– ethidiumbromide: [Sigma, Aldrich]
– running buffer: 1x TAE
– equipment: Electrophoresis DNA gel system [Promega]
– measurements/pictures: Snap Gene viewer
2.1.2 Surgical procedures
• Mice: Wild Type C57 B6 and MalKO mice were bred in the animal facility at
the institute of Immunology at the National University of Ireland, Maynooth
• As the MalKO mice were bred from controlled homozygous MalKO parents
only random samples were taken for genotyping. MalKO mice were also on
C57B6 background.
• Anaesthesia:
– MatrxTM Veterinary Anesthetic Gas Scavenger [Midmark]
– Medical Oxygen [BOC Medical]
– Filter: Active Scavenging Unit [VetTech Solutions LTD]
– Cage for anesthesia: [VetTech Solutions LTD]
– Anaesthetic: IsoFlo 100% w/w Inhalation Vapour, Liquid, Isoflurane 250
ml, [Abbott Laboratories Ltd]
2.1.3 30 day recovery and neuronal survival in the facial nucleus
• PBS (phosphate buffered saline, 0,1 M, pH = 7,4), [Life technologies]
• 4% solution Paraformaldehyde (PFA) [Sigma] in sterile PBS, pH 7,3
• Euthatal (Merial) Solution for injection [Merial Animal Health Ltd.], 200 mg
Pentobarbital Sodium in 1 ml, diluted to final concentration of 70 mg/ml
• Xylenes, [Sigma Aldrich]
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• Tissue Processor: ThermoShandon Citadel 1000, [ThermoShandon]
• Embedding Unit: Shandon Histocentre 2, [Shandon]
• Shandon Biopsy Cassettes with attached lid, [Thermo Electron Corporation]
• disposable Base Molds, [Simport]
• Menzel-Gla¨ser SUPERFROST R Plus, Microscope Slides, [Thermo Scientific]
• Microtome: Shandon Finesse 325, [Shandon]
• Chloroform, [Fisher Chemical]
• 0,1% [w/v] Cresyl violet solution, Cresyl Violet acetate, [Sigma]
• DPX mountant for microscopy, [BDH Laboratory Supplies]
• Cryotome: ThermoShandon
• Glue: [Fisher]
• Giemsa staining, Riedl Haen
• Fatpen: [DAKO]
Immunohistochemistry
• Vibratome: Integraslice 7550MM, [Campden Instruments]
• Primary antibodies:
– GFAP: rabbit anti GFAP, [DAKO Cytomation]
– IRAK-1: IRAK-1 (H273) rabbit polyclonal IgG, [Santa Cruz]
• Secondary antibody:
– Alexa Fluor 488, green, [invitrogen]
• Nuclear staining: DAPI [Roche]
• Neuro Trace, [Molecular Probes]
• Mounting Media: Aqua Poly/Mount Coverslipping Medium, [Polysciences
Inc.]
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Western blots
• NanoDrop 1000, [ThermoScientific]
• Odyssey Infrared Imager (Model 9120), [Li-Cor Biosciences]
• PBST (0,1% Tween)
• Tween 20, [Sigma Aldrich]
• N,N,N’,N’ Tetramethylenediamine (TEMED), [Sigma]
• Ultra Pure Protogel, [national diagnostics]
• 4X Laemmli Lower Tris (1,5 M Tris, 0,4% SDS, pH 8,8, with Tris Base)
• 4X Laemmli Upper Tris (0,5 M Tris, 0,4% SDS, pH 6,8, with Tris Base)
• 10X SDS Laemmli Running Buffer (0,25 M Tris, 1,92 M Glycine, 1% SDS, pH
8,3), diluted 1:10 for experiments
• Transfer Buffer (25 mM Tris Base, 0,2 M glycine, 20% methanol
• 3X Laemmli Sample Buffer (0,25 M Tris, 6% SDS, 40% glycerol, 0,04% Bro-
mophenol Blue, 20% 2-mercaptoethanol)
• Marker: Page Ruler TM Plus, Prestained Protein Ladder, [ThermoScientific]
• Primary Antibodies:
– CD11 b: rat anti mouse-CD11b, [eBioscience]
– GFAP: rabbit anti GFAP, [DAKO Cytomation]
– IRAK-1: IRAK-1 (H273) rabbit polyclonal IgG, [Santa Cruz]
– SH-PTP1: SH-PTP1 (C-19), rabbit polyclonal IgG, [Santa Cruz]
• Secondary antibody:
– Odyssey Goat anti-Rabbit IR Dye 800 CW, [Li-Cor Biosciences]
– Odyssey Goat anti-Mouse IR Dye 680, [Li-Cor Biosciences]
– Streptavidin (diluted 1:200) [Invitrogen]
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Figure 5: Ingredients for Lysisbuffer
Protein measurements
Preparation of Lysisbuffer (always prepare freshly!): Water was pipetted into a 50
ml tube and protease inhibitor tablets were dissolved. The tube was placed on ice
and all the ingredients of above table added and then vortexed until the IGEPAL
was completely dissolved. It was then centrifuged for 10 minutes at 3000 rpm to
dissolve the foam and the pH was adjusted at 7,3 with 2M NaOH. The buffer has
to be kept on ice.
2.2 Methods
2.2.1 Genotyping to guarantee homozygous MalKO in used mice
RNA-extraction
RNA-extraction was done exactly to the protocol of RNeasy FFPE Kit [Qiagen].
RT
2 µg of RNA were added into a sterile RNase-free 500 µl tube, with 1 µg random
primer and water was added to a total of 13,5 µl. The tube was heated to 70◦C for
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5 minutes, then immediately cooled on ice and spinned briefly to collect the solution
at the bottom. A mastermix was prepared consisting of M-MLV Reaction Buffer,
dNTPmix (1,25 µl), 10 mM dCTP (1,25 µl), 10 mM dGTP (1,25 µl), 10 mM dTTP
(1,25 µl), 25 units Recombinant RNasin R© Ribonuclease Inhibitor (40 u/µl) and 200
units M-MLV RT (200 u/µl) (all this amounts are per sample). 11,5 µl of mastermix
were added to each sample and mixed by gentle flicking. Tubes were incubated for
60 minutes at 37◦C, then incubated for 5 minutes at 95◦C and immediately put on
ice. Samples were stored at -20◦C until further use.
PCR
For the genotyping PCR 25 µl of Eppendorf R© HotMasterMix(2,5x) were placed in
a 500 µl eppendorf tube with 1,0 µl of either primer MAL A and MAL B (10 µM,
each) to check for WT mice or primer MAL B and MAL C (10 µM, each) to check
for MalKO mice and 23,0 µl distilled H2O and mixed. 1,0 µl of DNA was added and
the PCR amplification performed in a thermal cycler with the following parameters:
1) 95◦C for 5 minutes, 2) 95◦C for 30 seconds, 3) 60◦C for 30 seconds, 4) 72◦C for 1
minute, 5) 35 cycles of step 2 - 4, 6) 72◦C for 10 minutes; Both products were about
900 bp. To ensure the mouse in question is homozygous for WT or homozygous for
MalKO the DNA had to be tested for both (for MalKO: no signal in WT-primers
but signal for MalKO primers; for WT: signal for WT primers but no signal for
MalKO primers);
Agarose gel
Agarose gel was prepared from 1,125 g agarose mixed with 75 ml 1xTAE and was
dissolved by heating (microwave). 5 µl ethidiumbromide was added and the mixture
poured into a small gel casting (10 cm) tray with comb and let cool down for 30
minutes. Gel was placed in a gel electrophoresis apparatus (comb at the negative
end) and was submerged in running buffer (1xTAE) by a view millimetres. 5 µl
ethidiumbromide was added to the positive end of the tray and 15 µl sample was
loaded and run for 45 minutes. It was then viewed and photographed under UV
light with an exposure time of 80 ms.
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2.2.2 Surgical Procedures
Axotomy/crush facial nerve
All surgical instruments used in the surgical procedures were autoclaved and the
surgical area was disinfected with alcohol (70%). WT mice (n=3) and MalKO
mice (n=3) were deeply anesthetised with isoflurane, a small incision was made and
the left facial nerve was exposed posterior to the left ear. The facial nerve was
transsected at a point 2.0 mm inferior to the stylomastoid foramen. After suturing
the skin, animals were kept on a polystyrene tray until complete recovery. Success
of the facial nerve lesion was verified by observing ipsilateral whisker movement. All
axotomised animals presented a complete whisker paralysis.
Unoperated WT mice (n=3) and MalKO mice (n=3) as well as sham-operated WT
mice (n=3) and MalKO mice (n=3) were used as controls. Sham-operated animals
that consisted of mice that were anaesthetised as described above, the left facial
nerve was exposed posterior to the left ear but not cut, the skin was sutured and
the animals left on a polystyrene tray for complete recovery from anaesthesia. Sham
operated mice showed no signs of impairment of whisker movement and vibration.
The contralateral side of the brain was used as the internal control, as the facial
nerve is not anatomically connected with the contralateral side.
2.2.3 30 day recovery and neuronal survival in the facial nucleus
Monitoring of functional recovery in axotomised, nerve crushed and
sham-operated mice
Following axotomy mice were examined for functional whisker movement an vibra-
tion recovery by 2 independent observers. Whisker movement and vibration was
evaluated separately on a scale from 0 to 2 in 0,5 intervals. 0 representing no
movement/vibration at all and 2 representing full recovery with no visible difference
between the unleasionned, fully functional and lesioned side.
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Perfusion and paraffination of brains
Perfusion Untreated (WT: n=3, MalKO: n = 3), sham-operated (WT: n=3, MalKO:
n = 3), facial nerve axotomised (WT: n=3, MalKO: n = 3) mice were injected with
a lethal doses of 150 µl Euthatal [70 mg/ml], the thoractic cavity was then opened
and the animals were transcardially perfused with 10 ml sterile PBS, followed by
40 ml ice cold 4% PFA as fixative. Progress of the perfusion was monitored by the
typical signs of neck stiffness and discolouring of the liver. Once the perfusion was
finished, the brain was removed immediately and postfixed in 10 ml ice cold 4%
PFA, stored at 4◦C until used.
Paraffination Perfused brains were postfixed for 2 days in 4% PFA. They were
then incubated in 70% Ethanol for about 24 h. Brains were then trimmed and put
in special paraffin cassettes and transferred to an automatic tissue processor and
the paraffination process was following the instructions described below:
70% Ethanol for 1h (1x), 80% Ethanol for 1h (1x), 95% Ethanol for 1h each (2x),
100% Ethanol for 1h each (3x), 1:1 Ethanol/Xylene for 1h (1x), Xylene for 1h (2x),
hot Paraffin for 1h (1x);
The paraffinised brains were then collected and cast into paraffin disposable Base
Molds, by using the Shandon Histocenre 2, rostral side of the brain facing up and
caudal side attached to the holder.
Cutting, fixation and staining of paraffinated brain slices
Microtome sections of paraffinated brain slices Brains were installed in the
microtome and trimmed. The start of the facial nucleus was histologically verified
with a 10x magnification on the microscope until the 4th ventricle had changed
into a diamond like shape and the cerebellar flocculus had emerged laterally. From
there on 8 µm slices were cut, and transferred into cold tap water containing 25
ml Ethanol per litre. Slices were then immediately transferred to a hot water bath
(42◦C) to smooth out creases generated during cutting. Slices were then mounted
on microscope slides and left dry at RT until used. 240 brain slices were collected
per brain and stored at room temperature until used.
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Fixation and staining of paraffinated brain slices Slides were incubated on a
heating block for 1,5 hours at 56◦C. They were then placed on preheated plastic
plates and slowly cooled down for about 10’ at room temperature to avoid detach-
ment of slices during staining. Slides were then incubated in Xylene (2x 10 min)
and deparaffinated over night (for at least 10 hours) in 50:50 Ethanol:Chloroform.
The day after they were rehydrated in sequential baths of 100%, 95%, 70% and 50%
ethanol for 5 min each. They were then rinsed shortly in distilled and sterilised wa-
ter and let dry (for 3 minutes). Slides were then incubated for 5 min in 0,1% cresyl
violet solution, rinsed quickly in distilled and sterilised water and differentiated in
95% ethanol for 10 min. Finally slides were dehydrated for 2x 5 min in 100% ethanol
and 2x 5 min in Xylene and mounted with DPX.
Cryotome sections and Giemsa-staining of frozen brains
Cryotome sections Mouse brains which had been immediately frozen on dry ice
and had been stored at -70◦C are thawed slowly in the cryostat to a working tem-
perature of -20◦C. The brains were cut in half and glued to the specimen holder. 14
µm thick slices were cut with the specimen holder -19◦C and working temperature
-24◦C, then mounted on glass slides and stored at -70◦C.
Giemsa-Staining The tissue slices were dried for 30 seconds at room-temperature,
circled with fatpen and incubated in 4% PFA for 15 minutes. Afterwards they
were washed 3x 5 minutes in PBS and incubated for 55 seconds in Giemsa staining
solution. Then the slices were washed briefly 2x in distilled sterilised water.
2.2.4 Immunohistochemistry
Vibratome sections, staining and fixation of perfused brains
Vibratome sections A WT brain and a MalKO brain perfused with PFA and
incubated in PFA for 2 days were trimmed. A small piece of 2% Agarose was glued
to the specimen holder with super glue and the brain was glued to the Agarose with
the posterior side. The holder was filled up with PBS and slices were cut with the
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following parameters: Frequency 80 Hz, advance 1 mm / second, thickness: 25 µm.
A 24 well plate was prepared with 1 ml PBS per well and 3 slices per well were
incubated.
Staining The slices were transferred with a brush into PBST/BSA (5%) (in a 24
well plate) and blocked for 3 h on a rocker. One set of slices was incubated in IRAK-
1 antibody solution (1:500, in PBST/BSA(5%)), the second set was incubated in
GFAP antibody solution (1:500, in PBST/BSA (5%)). Both were left over night at
4◦C on a rocker. The next day both sets were washed three times 10 minutes in
PBST on a rocker and incubated in Alexa Fluor 488 secondary antibody (1:500, in
PBST/BSA(5%)) for 1 h also on a rocker. Again they were washed 3x 10 minutes
in PBST. Additionally DAPI and Neurotrace staining was performed (each 1:500 in
PBS) incubated for 1 h on a rocker and washed 1x 10 minutes in PBST.
Brain slices were then mounted on glass slides with Aqua Poly/mount mounting
media.
2.2.5 Western blots for protein levels of GFAP, SH-PTP1,
IRAK-1 and CD11b, in the facial nucleus at 2, 4 and 8
days post axotomy
Tissue collection and sample preparation
Normal control (WT: n = 3, MalKO: n =3), sham-operated (WT: n = 3, MalKO: n
=3) and lesioned (WT: n = 3, MalKO: n =3) mice were sacrificed by decapitation at
2, 4 and 8 days post axotomy. The brains were removed rapidly, the facial nucleus
dissected and transferred into 150 µl lysis buffer and immediately frozen in liquid
nitrogen. After thawing the samples on ice, the tissue was homogenised by using
a 23 G and a 27 G needle in a 1 ml syringe. The samples were again frozen in
liquid nitrogen, and thawed on ice. Again the solution was homogenised with a
27 G needle and then left on a shaker for 40 minutes at 4◦C. The samples were
centrifuged at 13 000 rpm for 10 minutes at 4◦C. The supernatant was transferred
into a new Eppendorf tube and the protein concentration was measured using the
33
Nanodrop at 289 nm. The protein concentration of the samples was normalised by
using lysis buffer. 3x sample buffer was added (to a final concentration of 1x) and
they were then boiled for 5 minutes at 95◦C. The samples were stored at -20◦C until
use.
Western Blot for GFAP, IRAK-1, Shp-1, CD11b
Western blot analysis of GFAP, IRAK-1, Shp-1 and CD11b was performed in sam-
ples of the facial nucleus, following 2, 4 and 8 days post facial nerve axotomy by
conventional sodium dodecyl sulfate (SDS)-polyacrylamide gel electrophoresis ac-
cording to [70]. For IRAK-1 and CD11b a 10% acrylamide gel was used, for GFAP
and Shp-1 a 12% acrylamide gel. 20 µl of each sample were loaded per well. The gels
were started at 90 V for 20 minutes and increased to 120 V for IRAK-1 and Shp-1
for 130 minutes, for GFAP and CD11b for 110 minutes. Following electrophoresis
gels were washed for 15 minutes in transfer buffer to equilibrate them, they were
then transferred onto nitrocellulose membrane (Whatman) using a semi dry blotting
system at 110 mA for 110 minutes (IRAK-1, CD11b) and 100 minutes (GFAP, Shp-
1). Membranes were then blocked with 5% milk/PBS for 1 hour and incubated over
night on a roller at 4◦C with the according antibody: rabbit anti IRAK-1 antibody
(diluted 1:1000) in 5% milk/PBST, rabbit anti SH-PTP1 antibody (diluted 1:2000)
in 5% milk/PBST, rabbit anti CD11b (diluted 1:2000) in 5% milk/PBST, rabbit
anti GFAP antibody (diluted 1:2000) in 5% milk/PBST. The next day the blots
for IRAK-1, GFAP and Shp-1 were washed 3x 15 min in PBST at room tempera-
ture on a roller and incubated for 1 h with a goat anti-rabbit secondary antibody
(diluted 1,2:5000) in 5% milk/PBST on a roller at room temperature. Blots were
washed 3x 15 min in PBST and 1x 30 min in PBS and scanned using the LiCor
Odyssey scanner system (700 nm). Membranes for CD11b were then washed 3x 5
minutes in TBST (0,05% Tween), 1x 5 minutes in 0,1% BSA/TBST(0,05% Tween)
and were incubated in streptavidin (diluted 1:200) for 1 h at room temperature. In
the dark room 1,5 ml of solution A and 1,5 ml of solution B (per blot) were mixed
and applied to the blot, covering it completely for about 3 minutes. The blot was
placed between two layers of transparency film, in a light proof film cassette. The
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two layers were sealed with tape, 2 layers of photo film were placed on top (results in
less exposure of the upper film) and the cassette closed and incubated for 5 minutes.
Exposed photo films were developed until the bands were visible, they were then
rinsed briefly in water, and fixed for 3 minutes, then rinsed in water and left to dry.
The blots were then scanned and digitalised.
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3 Results
3.1 Genotyping
Genotyping was done with three primers (A, B and C), with A and B being spe-
cific for WT-mice and B and C being specific for MalKO-mice. As both products
had the same size, the genotyping of each sample had to be done for both primer
combinations with A and B being negative while B and C being positive to confirm
homozygous MalKO-mice. Fig. ?? shows the product for WT (second lane) and the
product for MalKO (third lane).
Figure 6: The product for WT as well as the product
for MalKO are around 900 bp. Water was
used as a control.
3.2 Recovery 31 days post axotomy
3.2.1 Functional Recovery is Impaired in MalKO mice
Observation of functional recovery of whisker vibration and movement had shown a
marked difference in recovery between WT mice and MalKO mice. Whisker vibra-
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Figure 7: Recovery of vibration (A+C) and movement (B+D) (depicted as graph in A and B
or dots with errorbars in C and D) of whiskers observed through 31 days post facial
nerve axotomy in WT and MalKO mice. Recovery of vibration was delayed and
massively impaired in MalKO compared to WT mice which made a full recovery
at the end of the observation period (31 days) (A+C). Recovery of movement was
only slightly delayed in the onset, only to fall back into complete paralysis from
day 20 on (B+D).
tion recovery had started slightly delayed in MalKO mice and roughly parallel with
the recovery of WT mice up until day 7. At that point the first stagnation in MalKO
recovery (at a rating of 0,83 out of 2) became visible. From day 15 on a decrease in
functionality had taken place and had stagnated at a significantly lower rate than
in WT mice of 0,67 (out of 2) around day 20. WT whisker vibration recovery had
slowed down but was constantly taken place up to a full recovery (rated with 2 out
of 2) around day 29 (see Fig. 7A and C). Whisker movement recovery had started
off equally in WT and MalKO mice and went along nearly parallel but again with
a slight delay in MalKO mice up to day 15, where both had been rated at 0,5 (out
of 2). From day 15 on, WT mice recovery had proceeded and stabilised at 1 (out of
2) around day 26. MalKO mice whisker movement on the other hand had declined
rapidly from 0,5 (out of 2) to 0 (out of 2) from day 15 to day 24 with no further
development up to the end of the observation time at day 31 (Fig. 7B and D).
Summarising whisker vibration had recovered fully in WT mice after 31 days and
only to a rating of 0,5 (out of 2) in MalKO mice (see Fig. 8A). Whisker movement
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Figure 8: Recovery of vibration (A) movement (B) of whiskers at the end of the 31 days
observation periode post peripheral facial nerve axotomy in WT and MalKO mice.
WT mice show full recovery of whisker vibration of the injured side, compared to
the contralateral side, while in MalKO the rating reaches only 0,67 (out of 2) (A).
Whisker movement recovery arrives at 1 (out of 2) in WT mice on day 31, while
in MalKO mice there is no movement in the ipsilateral side visible at 0 (out of 2),
compared to the contralateral, uninjured side (B).
had only recovered up to 1 (out of 2) in WT mice, but had shown no lasting recovery
at all in MalKO mice (0 out of 2), (see Fig. 8B)
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3.2.2 Neuronal survival 31 days post axotomy
Figure 9: Facial Nucleus: Cresyl violet staining of 8 µm paraffinated coronal brainslices of
WT and MalKO mice. Micrographs show the facial motor nucleus in mice with
facial nerve axotomy, 31 days post operation compared to the lesioned side of the
same mouse (A) WT contralateral facial nucleus; (B) WT ipsilateral facial nucleus;
(C) MalKO contralateral facial nucleus; (D) MalKO contralateral facial nucleus;
Facial nerve axotomy in WT and MalKO mice led to severe motoneuron loss 31
days post lesion. Fig. 2 shows the rather dramatic loss of motoneurons in the facial
nucleus. Fig. 9A shows the facial nucleus on the unlesioned side of a WT mouse
while Fig. 9B represents the ipsilateral facial nucleus, where the loss of cells 31 days
post facial nerve axotomy is clearly visible. Fig. 9C depicts the unlesioned side of
a MalKO mouse while Fig. 9D shows the axotomised side of same mouse, again
showing significant cell loss.
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Figure 10: Neuronal survival: remaining neurons of the facial nucleus 31 days post peripheral facial
nerve axotomy have been counted in the ipsilateral and contralateral nucleus. The
percentage of survival was calculated compared to the unlesioned (contra lateral) side.
Controls used were completely untreated mice and sham operated mice. Untreated mice
and sham operated mice show no significant difference between the ipsi and contralateral
side (untreated WT: 106,9% ± 8,2%, untreated MalKO: 101,8% ±13,2%; sham operated
WT: 94,3% ± 1,4%, sham operated MalKO: 95,7% ± 4,9%; all mean ± SD, n=3). There
is a significant difference in the neuronal survival between WT mice (60,1% ± 5,0%,
mean ± SD) and MalKO mice (50,5% ± 5,1%, mean ± SD, n=3) with a P¡0,05 in
one-sided unpaired t test.
As shown in Fig. 10 there is no significant difference between the ipsilateral and
the contralateral side in untreated and in sham operated mice. These were used
as controls for an eventual influence of the surgery itself. Motoneuron survival in
axotomised mice accounts in WT for 60,1 ± 5,1% (mean ± SD, n=3), compared to
MalKO mice where neuronal survival is significantly lower at 50,5 ± 5,1% (mean
± SD, n=3). The used one-sided unpaired t test shows a p value lower than 0,05.
Here the lack of MAL is clearly responsible for a higher cell death in the ipsilateral
facial nucleus.
40
3.3 Changes in GFAP, IRAK-1, Shp-1 and CD11b
protein levels
3.3.1 GFAP protein level is higher in MalKO mice following
facial nerve axotomy compared with WT
Figure 11: (A) Representative protein double band for GFAP showing clearly the increased
expression in the upper band of the two signals for GFAP. (B) Figure showing
relative protein levels of GFAP in the ipsilateral facial nucleus. Western blot
results were normalised with beta-Actin and depicted relative to untreated WT-
levels of GFAP. Clearly visible from day four on there is a trend to strongly
increased levels of GFAP in MalKO mice, compared to WT.
Relative protein levels within the facial nucleus were determined for GFAP as a
marker for astrocytic activation with tissue samples of the ipsilateral facial nucleus
at 2, 4 and 8 days post facial nerve axotomy. Levels of GFAP increase in WT mice
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post axotomy, as astrocytes get activated. When observing only the upper band of
the GFAP signal (Fig. 11A), significant differences between the protein levels in WT
and MalKO mice were observed, showing a stronger activation of astrocytes already
at day 4 in MalKO mice, even more pronounced at day 8 (see Fig. 11B). All results
were depicted relative to untreated WT-protein levels as controls.
3.3.2 IRAK-1 protein levels decrease in MalKO mice following
facial nerve axotomy compared with WT
Figure 12: Relative protein levels of IRAK-1 in the facial nucleus. IRAK-1 protein levels
were higher in the axotomised mice than in the controls on day 2 in both, WT and
MalKO mice. While WT protein levels rise further at 4 and 8 days post axotomy,
for MalKO mice protein levels a trend was observed towards a decreased amount
of IRAK-1. We have observed a delayed and less important increase in the levels
of IRAK-1 within the ipsilateral Facial nuclei following injury in MalKO mice
related to controls.
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Relative Protein levels for IRAK-1 within the facial nucleus were also observed
post axotomy. Fig. 12A shows the results of the western blots, while Fig. 12B shows
the relative protein levels. Although in both, WT and MalKO mice levels were
slightly elevated after two days and increased further in WT mice 4 and 8 days post
facial nerve axotomy, in MalKO mice an entirely different trend can be observed.
After a small increase at day 2 protein levels of IRAK-1 in MalKO mice decrease
below control levels at day 4 and even further at day 8.
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3.3.3 Shp-1 protein levels are lower in MalKO mice following
facial nerve axotomy compared with WT
Figure 13: Analysis of relative Shp-1 levels in the ipsilateral facial nucleus relative to un-
treated WT levels showed as a trend slightly lower expression levels of Shp-1 in
MalKO mice at 2, 4 and 8 days post axotomy. In general, relative WT levels
are higher at all observed time-points. In MalKO levels of Shp-1 there is still a
tendency to higher relative levels than in the untreated control group.
Shp-1 protein levels within the axotomised facial nucleus are higher than IRAK-1
with concentrations in MalKO mice being lower than in WT (Fig. 13) at all observed
time-points. In MalKO mice the relative protein levels of Shp-1 are still higher than
in the uninjured control group. In general both, WT and MalKO Shp-1 levels seem
to peak at day 4, but this needs to be confirmed by another experiment with a
bigger number of animals per group.
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3.3.4 CD11b shows no specific trend following facial nerve
axotomy compared with WT
Figure 14: Relative CD11b protein levels in the facial nucleus after facial nerve axotomy.
Relative protein levels of the MalKO mice are slightly lower than in the WT
mice. There is no trend visible in the axotomised mice.
Relative protein levels of CD11b within the facial nucleus in axotomised mice
were determined as a marker for microglial activation following peripheral facial
nerve axotomy. Although in the control mice the relative MalKO CD11b levels
are slightly lower compared to the WT, they show no specific difference between
WT and MalKO in the axotomised mice (Fig. 13). Also the expected elevation of
CD11b protein levels in WT mice does not take place. This might be the case due
to the choice of a too short observation time as well as procedural difficulties in the
experiment and also would need to be repeated with bigger sample sizes.
45
4 Discussion
The results of this thesis will be briefly summarised as follows: MalKO mice show a
delayed and impaired functional recovery of whisker movement in a 31 days period
compared to the WT mice after peripheral facial nerve axotomy. In agreement with
this data it has also been shown, that the motoneuron loss in the facial nucleus is
significantly higher in MalKO mice than in WT mice. Additionally we observed
increased levels of GFAP as a marker for astrocyte activation in axotomised MalKO
mice compared to WT mice.
4.1 Functional recovery of whisker movement after
peripheral facial nerve axotomy
In my project functional recovery of whisker movement and vibration was observed
during a period of 31 days post peripheral facial nerve axotomy. It was estimated
by comparing movement and vibration of the ipsilateral (injured) side with the con-
tralateral (non-injured) side. Recovery was progressing nearly parallel in WT and
MalKO mice right up to day 15. From there on a clear deterioration of functional
recovery was observed in MalKO mice whereas the regeneration progressed in WT
mice. Kamijo et al. [67] and others have shown, that after peripheral facial nerve
crush mice recovered fully within 13 days. In facial nerve-transected animals the re-
covery time for full recovery was observed to be more than 10 weeks [71]. Within the
31 days of observation, the trend shown in WT mice recovery follows this findings.
Additionally to the peak in astrocytic activation around day 14 after peripheral
facial nerve axotomy in mice, a peak in both, neuronal cell death [74] and acti-
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vated T-Lymphocyte infiltration [72, 44] have been observed. This occurs despite
an intact Blood Brain Barrier (BBB) and specifically only in areas of degenerating
neurons and activated phagocytic microglia [44]. The lymphocytic infiltration was
also accompanied by a peak in the expression of interleukin-1 beta (IL-1β), tumor
necrosis factor-alpha (TNFα) and interferon-gamma (IFNγ). Expression levels of
those proinflammatory cytokines - mainly IL-1β and TNFα - have been shown to
play a key role in recruiting CD3+ T-lymphocytes into the facial nucleus after pe-
ripheral nerve axotomy [72]. Different levels of those cytokines and different levels of
CD3+ T-cells in MalKO mice compared to WT mice might present an explanation
for the deterioration in functional recovery in MalKO-mice from day 15 on. Two
possible explanations would be either a higher proinflammatory response, creating
an increase in neuronal cell death or a lower response in cell survival associated
pathways. Additionally it has been shown that inflammation is needed for regen-
eration [73]. Complete inhibition of inflammation has been shown to be extremely
detrimental for regenerative processes and neuronal survival. The determination
of the levels of the proinflammatory cytokines and CD3+ T-cell infiltration in the
MalKO mouse facial nucleus, following peripheral facial nerve axotomy remain to
be elucidated.
4.2 Neuronal cell death is higher in MalKO mice than
in WT-mice
After observing functional recovery during 31 days axotomised mice were sacrificed
and brain-slices were prepared at the level of the facial nuclei, stained with cresyl
violet to study neuronal death in the facial nucleus after peripheral nerve axotomy.
The sham-operated controls did not display any significant differences between the
ipsilateral and the contralateral uninjured side. Also there was only a marginal
insignificant difference in the absolute numbers of neurons in the facial nucleus be-
tween normal non injured MalKO and WT mice. Other studies in adult mice have
shown degeneration of 20-35% of motoneurons in the facial nucleus after periph-
eral facial nerve transsection [74, 75]. Our own numbers of neuronal death in WT
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mice are higher but stable at 40% ± 5% (mean ± SD; n=3) which might be due to
methodological differences. In MalKO mice we have found a small but very consis-
tent reduction of cell survival of 10% to 50% ±5% (mean ± SD; n=3) confirming
the observation of impaired functional recovery in MalKO mice. MAL is a key
player in the activation of NFκB, which is a major protein complex, controlling the
transcription of a number of proinflammatory cytokines. NFκB plays also a role in
modulating nerve regeneration following peripheral nerve injury [76]. Within the
experimental context described above one can argue that in our model the lack of
MAL signalling has an influence on peripheral nerve regeneration [77].
Our controls of Sham operated WT as well as MalKO mice show no signs for
neuronal cell death in the facial nucleus, confirming the method of peripheral facial
nerve axotomy as not interfering in motoneuron survival.
4.3 GFAP, Shp-1, CD11b, IRAK-1
Our experiments have shown an increase in GFAP levels after peripheral facial nerve
injury in WT. This indicates - in accordance with the literature [42] - activation of
astrocytes. We have observed a significantly higher expression of GFAP in MalKO
mice, following the lesion, which is certainly an indication of stronger inflammatory
response.
Horvat et al.[78] have shown, that SHP-1 is upregulated in activated microglia
and astrocytes after peripheral nerve injury. Whereas in adult moth eaten viable
(mev/mev) mice, known to have a reduced SHP-1 activity, a strong astrocytic ac-
tivation (verified by GFAP-levels) but neither number nor morphology of microglia
seemed to be modified. These findings are in accordance with our own results where
a higher astrocytic activation takes place (indicated by increased GFAP-levels) in
MalKO mice, where we simultaneously observe lower levels of SHP-1. At the same
time the results for CD11b as a marker for microglial activation were not significant
in any direction in MalKO mice. In WT mice there seems to be a trend to elevated
protein levels for CD11b, although further experiments will be necessary to verify
this trend. One possible explanation might be the short term observation of the
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early signals at 2, 4 and 8 days, where the most intense peak for glial activation has
been shown to be found between day 8 and 14 [42]. There might also be no clear
trend visible, as these experiments have been done with only 3 mice per group, and a
larger set of animals should be used in further investigations to get more statistically
significant data.
It could be hypothesised that MAL plays a role in activating Shp-1, which would
explain the decreased Shp-1 levels in MalKO mice. Indeed MAL contains an im-
munoreceptor tyrosine-based inhibition motif (ITIM), that is a conserved sequence
of amino acids (S/I/V/LxYxxI/V/L) that is found in membrane bound and cy-
toplasmic molecules. ITIM motifs can be phosphorylated by members of the Src
kinase family. Phosphorylated ITIMs can then recruit other enzymes such as the
phosphotyrosine phosphatases SHP-1 and SHP-2, or the inositol-phosphatase called
SHIP. Consequently, in our model system the lack of MAL in MalKO mice may be
responsible for the lower levels of SHP-1 observed [79].
IRAK-1 is a kinase known to be a negative regulator of NFκB (REF). NFκB
in turn is important for inflammatory responses in the CNS including astrocyte
activation. The fact that we observed significantly elevated GFAP levels in MalKO
mice compared to WT mice in addition to lower levels of IRAK-1 expression is
consistent with a possible stronger inflammatory response. Strong NFkB activation
- due to a lower regulatory influence of IRAK-1 - might therefore be the reason why
we observed reduced functional recovery in MalKO mice.
As Raivich et al. [72] have shown in WT-mice, the NFκB pathway and secretion
of cytokines play a vital role in the functional recovery following peripheral facial
nerve axotomy. This inflammatory response appears to be important for neuronal
cell survival and recovery as shown by Schwartz et al.[73] who has found protection
of secondary neuronal degeneration after optical nerve crush by autoimmune T-cells.
The peak of T-cell infiltration into the injured brain occurs around day 14 following
the lesion where they aggregate around neuronal debris surrounded by phagocytic
microglia. This correlates with the rapid regression in functional recovery of whisker
movement in MalKO mice after day 15 post axotomy in our setup.
One could hypothesise that the absence of Mal leads to impaired NFκB activa-
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tion and subsequently abolished or at least delayed and limited excretion of proin-
flammatory cytokines (IL1β, TNFα, IFNγ) resulting in insufficient recruitment of
T-cells [72]. More likely the balance between inflammatory and protective response
is severely disturbed by an increased inflammatory response, creating more neurode-
generative damage. Interestingly Kilic et al. [80] has reported a protective effect of
TLR-4 deficiency in axotomy induced neurodegeneration in retinal ganglion cell ax-
otomy in TLR4 deficient mice. Though this might be due to the observation period
of only 14 days, where in our setting recovery just started to discontinue in MalKO
mice.
Figure 15 depicts a hypothetical model based on our results, presenting a possible
explanation for the impaired functional recovery and increased neuronal cell death
in MalKO mice after peripheral facial nerve axotomy.
Figure 15: Depiction of a hypothetical model which would result in lower functional recovery
and decreased neuronal survival in MalKO mice and is supported by our experi-
mental results. Therefore the decreased levels of IRAK-1 found in MalKO mice
might lead to increased NFκB activation, followed by a more severe inflammatory
response, which would lead to significantly increased neuronal cell damage, thus
preventing functional recovery and decreasing neuronal regeneration.
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Therefore, with the inhibiting effects of IRAK-1 on NFkB activation no longer
existing, one could assume a higher NFκB activation, which would be leading to an
enhanced release of mainly proinflammatory cytokines. This fact, possible combined
with a stronger cytotoxical T-cell recruitment and activation would necessarily lead
to increased neuronal cell death and therefore naturally to decreased recovery in
MalKO mice. The actual levels for NFκB and proinflammatory cytokines remain to
be determined in further experiments as well as the amount of infiltrating T-cells.
4.4 Conclusions
MAL / TIRAP is a crucially important signalling molecule for TLR2 and TLR4
leading to NFKB activation and proinflammatory cytokines secretion.
Data produced in this work shows that MAL may play a role in facial motoneuron
survival, peripheral facial nerve regeneration, facial nerve functional recovery and
CNS glial activation following sterile Facial nerve peripheral lesion.
Our work raised three fundamental questions:
First, how can CNS glia “sense danger” and become activated following peripheral
nerve injury that has occurred remotely from the CNS?
Second, what is the nature of the “signals” involved in glial activation in response
to nerve injury?
Third, how do these “signals” interact with glial cells and control their activation
state and function?
Further studies should be performed to gain a better understanding of the role
of MAL in the mechanisms underlying CNS inflammation and nerve regeneration
following peripheral nerve injury.
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